[1]Y. Koteswara Rao, G. Vimalamma, C. V. Rao, and Y. M. Tzeng, "Flavonoids and andrographolides from Andrographis paniculata," Phytochemistry, vol. 65, pp. 2317-21, Aug 2004.
[2]N. Y. Chiu and K. H. Chang, "The Illustrated Medicinal Plants of Taiwan," Southern Materials Center Publishing Inc., vol. 3, p. 210~211, 1998.
[3]K. Jarukamjorn and N. Nemotob, "Pharmacological Aspects of Andrographis paniculata on Health and Its Major Diterpenoid Constituent Andrographolide," Journal of Health Science, vol. 54, pp. 370-381, June 2008.
[4]王國仁, "穿心蓮內酯的微生物與化學轉換," in 藥學系碩士論文. vol. 碩士: 臺北醫學大學, 2004.[5]W. F. Chiou, J. J. Lin, and C. F. Chen, "Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide," Br J Pharmacol, vol. 125, pp. 327-34, Sep 1998.
[6]W. F. Chiou, C. F. Chen, and J. J. Lin, "Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide," Br J Pharmacol, vol. 129, pp. 1553-60, Apr 2000.
[7]K. Sheeja, P. K. Shihab, and G. Kuttan, "Antioxidant and anti-inflammatory activities of the plant Andrographis paniculata Nees," Immunopharmacol Immunotoxicol, vol. 28, pp. 129-40, 2006.
[8]Y. C. Shen, C. F. Chen, and W. F. Chiou, "Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide," Planta Med, vol. 66, pp. 314-7, May 2000.
[9]Y. C. Shen, C. F. Chen, and W. F. Chiou, "Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect," Br J Pharmacol, vol. 135, pp. 399-406, Jan 2002.
[10]C. Wiart, K. Kumar, M. Y. Yusof, H. Hamimah, Z. M. Fauzi, and M. Sulaiman, "Antiviral properties of ent-labdene diterpenes of Andrographis paniculata nees, inhibitors of herpes simplex virus type 1," Phytother Res, vol. 19, pp. 1069-70, Dec 2005.
[11]A. R. N. Najib Nik, T. Furuta, S. Kojima, K. Takane, and M. Ali Mohd, "Antimalarial activity of extracts of Malaysian medicinal plants," J Ethnopharmacol, vol. 64, pp. 249-54, Mar 1999.
[12]S. S. Handa and A. Sharma, "Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride," Indian J Med Res, vol. 92, pp. 276-83, Aug 1990.
[13]S. S. Handa and A. Sharma, "Hepatoprotective activity of andrographolide against galactosamine & paracetamol intoxication in rats," Indian J Med Res, vol. 92, pp. 284-92, Aug 1990.
[14]A. Kapil, I. B. Koul, S. K. Banerjee, and B. D. Gupta, "Antihepatotoxic effects of major diterpenoid constituents of Andrographis paniculata," Biochem Pharmacol, vol. 46, pp. 182-5, Jul 6 1993.
[15]N. P. Trivedi and U. M. Rawal, "Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice," Indian J Exp Biol, vol. 39, pp. 41-6, Jan 2001.
[16]N. Yoopan, P. Thisoda, N. Rangkadilok, S. Sahasitiwat, N. Pholphana, S. Ruchirawat, and J. Satayavivad, "Cardiovascular effects of 14-deoxy-11,12-didehydroandrographolide and Andrographis paniculata extracts," Planta Med, vol. 73, pp. 503-11, Jun 2007.
[17]C. Y. Zhang and B. K. Tan, "Mechanisms of cardiovascular activity of Andrographis paniculata in the anaesthetized rat," J Ethnopharmacol, vol. 56, pp. 97-101, Apr 1997.
[18]R. A. Kumar, K. Sridevi, N. V. Kumar, S. Nanduri, and S. Rajagopal, "Anticancer and immunostimulatory compounds from Andrographis paniculata," J Ethnopharmacol, vol. 92, pp. 291-5, Jun 2004.
[19]S. Rajagopal, R. A. Kumar, D. S. Deevi, C. Satyanarayana, and R. Rajagopalan, "Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata," J Exp Ther Oncol, vol. 3, pp. 147-58, May-Jun 2003.
[20]H. Y. Cheung, S. H. Cheung, J. Li, C. S. Cheung, W. P. Lai, W. F. Fong, and F. M. Leung, "Andrographolide isolated from Andrographis paniculata induces cell cycle arrest and mitochondrial-mediated apoptosis in human leukemic HL-60 cells," Planta Med, vol. 71, pp. 1106-11, Dec 2005.
[21]J. Li, H. Y. Cheung, Z. Zhang, G. K. Chan, and W. F. Fong, "Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species," Eur J Pharmacol, vol. 568, pp. 31-44, Jul 30 2007.
[22]J. Zhou, S. Zhang, C. N. Ong, and H. M. Shen, "Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells," Biochem Pharmacol, vol. 72, pp. 132-44, Jul 14 2006.
[23]A. Puri, R. Saxena, R. P. Saxena, K. C. Saxena, V. Srivastava, and J. S. Tandon, "Immunostimulant agents from Andrographis paniculata," J Nat Prod, vol. 56, pp. 995-9, Jul 1993.
[24]T. Matsuda, M. Kuroyanagi, S. Sugiyama, K. Umehara, A. Ueno, and K. Nishi, "Cell differentiation-inducing diterpenes from Andrographis paniculata Nees," Chem Pharm Bull (Tokyo), vol. 42, pp. 1216-25, Jun 1994.
[25]C. Calabrese, S. H. Berman, J. G. Babish, X. Ma, L. Shinto, M. Dorr, K. Wells, C. A. Wenner, and L. J. Standish, "A phase I trial of andrographolide in HIV positive patients and normal volunteers," Phytother Res, vol. 14, pp. 333-8, Aug 2000.
[26]R. S. Chang, L. Ding, G. Q. Chen, Q. C. Pan, Z. L. Zhao, and K. M. Smith, "Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus," Proc Soc Exp Biol Med, vol. 197, pp. 59-66, May 1991.
[27]A. Basak, S. Cooper, A. G. Roberge, U. K. Banik, M. Chretien, and N. G. Seidah, "Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters," Biochem J, vol. 338 ( Pt 1), pp. 107-13, Feb 15 1999.
[28]M. I. Iruretagoyena, J. A. Tobar, P. A. Gonzalez, S. E. Sepulveda, C. A. Figueroa, R. A. Burgos, J. L. Hancke, and A. M. Kalergis, "Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse," J Pharmacol Exp Ther, vol. 312, pp. 366-72, Jan 2005.
[29]M. A. Akbarsha and P. Murugaian, "Aspects of the male reproductive toxicity/male antifertility property of andrographolide in albino rats: effect on the testis and the cauda epididymidal spermatozoa," Phytother Res, vol. 14, pp. 432-5, Sep 2000.
[30]S. Nanduri, V. K. Nyavanandi, S. S. Thunuguntla, S. Kasu, M. K. Pallerla, P. S. Ram, S. Rajagopal, R. A. Kumar, R. Ramanujam, J. M. Babu, K. Vyas, A. S. Devi, G. O. Reddy, and V. Akella, "Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents," Bioorg Med Chem Lett, vol. 14, pp. 4711-7, Sep 20 2004.
[31]C. C. Chen, Y. J. Shiao, R. D. Lin, Y. Y. Shao, M. N. Lai, C. C. Lin, L. T. Ng, and Y. H. Kuo, "Neuroprotective diterpenes from the fruiting body of Antrodia camphorata," J Nat Prod, vol. 69, pp. 689-91, Apr 2006.
[32]M. A. Hidalgo, A. Romero, J. Figueroa, P. Cortes, Concha, II, J. L. Hancke, and R. A. Burgos, "Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells," Br J Pharmacol, vol. 144, pp. 680-6, Mar 2005.
[33]T. Wang, B. Liu, W. Zhang, B. Wilson, and J. S. Hong, "Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation," J Pharmacol Exp Ther, vol. 308, pp. 975-83, Mar 2004.
[34]P. K. Singha, S. Roy, and S. Dey, "Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees. against ethanol-induced toxicity in mice," J Ethnopharmacol, vol. 111, pp. 13-21, Apr 20 2007.
[35]P. Thisoda, N. Rangkadilok, N. Pholphana, L. Worasuttayangkurn, S. Ruchirawat, and J. Satayavivad, "Inhibitory effect of Andrographis paniculata extract and its active diterpenoids on platelet aggregation," Eur J Pharmacol, vol. 553, pp. 39-45, Dec 28 2006.
[36]E. Amroyan, E. Gabrielian, A. Panossian, G. Wikman, and H. Wagner, "Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation," Phytomedicine, vol. 6, pp. 27-31, Mar 1999.
[37]P. K. Visen, B. Shukla, G. K. Patnaik, and B. N. Dhawan, "Andrographolide protects rat hepatocytes against paracetamol-induced damage," J Ethnopharmacol, vol. 40, pp. 131-6, Oct 1993.
[38]C. Zhang, M. Kuroyangi, and B. K. Tan, "Cardiovascular activity of 14-deoxy-11,12-didehydroandrographolide in the anaesthetised rat and isolated right atria," Pharmacol Res, vol. 38, pp. 413-7, Dec 1998.
[39]C. Y. Zhang and B. K. Tan, "Effects of 14-deoxyandrographolide and 14-deoxy-11,12-didehydroandrographolide on nitric oxide production in cultured human endothelial cells," Phytother Res, vol. 13, pp. 157-9, Mar 1999.
[40]R. E. Kamdem, S. Sang, and C. T. Ho, "Mechanism of the superoxide scavenging activity of neoandrographolide - a natural product from Andrographis paniculata Nees," J Agric Food Chem, vol. 50, pp. 4662-5, Jul 31 2002.
[41]J. Liu, Z. T. Wang, L. L. Ji, and B. X. Ge, "Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage," Mol Cell Biochem, vol. 298, pp. 49-57, Apr 2007.
[42]J. Batkhuu, K. Hattori, F. Takano, S. Fushiya, K. Oshiman, and Y. Fujimiya, "Suppression of NO production in activated macrophages in vitro and ex vivo by neoandrographolide isolated from Andrographis paniculata," Biol Pharm Bull, vol. 25, pp. 1169-74, Sep 2002.
[43]J. Liu, Z. T. Wang, and L. L. Ji, "In vivo and in vitro anti-inflammatory activities of neoandrographolide," Am J Chin Med, vol. 35, pp. 317-28, 2007.
[44]D. Armstrong and R. Browne, "The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory," Adv Exp Med Biol, vol. 366, pp. 43-58, 1994.
[45]J.-i. Abe and B. C. Berk, "Reactive Oxygen Species as Mediators of Signal Transduction in Cardiovascular Disease," Trends in Cardiovascular Medicine, vol. 8, pp. 59-64, February, 1998 1998.
[46]李奇翰, "靈芝抗癌效果之研究," in 醫事技術學研究所碩士論文. vol. 碩士: 國立臺灣大學, 2001.[47]J. Cadet and M. Berger, "Radiation-induced decomposition of the purine bases within DNA and related model compounds," Int J Radiat Biol Relat Stud Phys Chem Med, vol. 47, pp. 127-43, Feb 1985.
[48]B. N. Ames, M. K. Shigenaga, and T. M. Hagen, "Oxidants, antioxidants, and the degenerative diseases of aging," Proc Natl Acad Sci U S A, vol. 90, pp. 7915-22, Sep 1 1993.
[49]K. Maundrell, B. Antonsson, E. Magnenat, M. Camps, M. Muda, C. Chabert, C. Gillieron, U. Boschert, E. Vial-Knecht, J. C. Martinou, and S. Arkinstall, "Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1," J Biol Chem, vol. 272, pp. 25238-42, Oct 3 1997.
[50]M. Schreiber, A. Kolbus, F. Piu, A. Szabowski, U. Mohle-Steinlein, J. Tian, M. Karin, P. Angel, and E. F. Wagner, "Control of cell cycle progression by c-Jun is p53 dependent," Genes Dev, vol. 13, pp. 607-19, Mar 1 1999.
[51]M. Faris, N. Kokot, K. Latinis, S. Kasibhatla, D. R. Green, G. A. Koretzky, and A. Nel, "The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression," J Immunol, vol. 160, pp. 134-44, Jan 1 1998.
[52]M. Faris, K. M. Latinis, S. J. Kempiak, G. A. Koretzky, and A. Nel, "Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter," Mol Cell Biol, vol. 18, pp. 5414-24, Sep 1998.
[53]S. G. Shiah, S. E. Chuang, Y. P. Chau, S. C. Shen, and M. L. Kuo, "Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor beta-lapachone-induced apoptosis through an oxidation-dependent pathway," Cancer Res, vol. 59, pp. 391-8, Jan 15 1999.
[54]C. A. Colton, L. Fagni, and D. Gilbert, "The action of hydrogen peroxide on paired pulse and long-term potentiation in the hippocampus," Free Radic Biol Med, vol. 7, pp. 3-8, 1989.
[55]T. C. Pellmar, G. E. Hollinden, and J. M. Sarvey, "Free radicals accelerate the decay of long-term potentiation in field CA1 of guinea-pig hippocampus," Neuroscience, vol. 44, pp. 353-9, 1991.
[56]R. H. Woodruff and R. J. Franklin, "Growth factors and remyelination in the CNS," Histol Histopathol, vol. 12, pp. 459-66, Apr 1997.
[57]J. W. Liu, Y. J. Yu, P. Y. Zheng, X. D. Zhang, T. Li, Y. Cao, and M. C. Guo, "Synergistic protective effect of picroside II and NGF on PC12 cells against oxidative stress induced by H2O2," Pharmacol Rep, vol. 59, pp. 573-9, Sep-Oct 2007.
[58]J. Chandra, A. Samali, and S. Orrenius, "Triggering and modulation of apoptosis by oxidative stress," Free Radic Biol Med, vol. 29, pp. 323-33, Aug 2000.
[59]K. G. Manton, S. Volovik, and A. Kulminski, "ROS effects on neurodegeneration in Alzheimer''s disease and related disorders: on environmental stresses of ionizing radiation," Curr Alzheimer Res, vol. 1, pp. 277-93, Nov 2004.
[60]C. G. Cochrane, "Mechanisms of oxidant injury of cells," Mol Aspects Med, vol. 12, pp. 137-47, 1991.
[61]S. Orrenius, D. J. McConkey, G. Bellomo, and P. Nicotera, "Role of Ca2+ in toxic cell killing," Trends Pharmacol Sci, vol. 10, pp. 281-5, Jul 1989.
[62]B. Halliwell and J. M. Gutteridge, "Oxygen toxicity, oxygen radicals, transition metals and disease," Biochem J, vol. 219, pp. 1-14, Apr 1 1984.
[63]B. Halliwell and J. M. Gutteridge, "Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts," Arch Biochem Biophys, vol. 246, pp. 501-14, May 1 1986.
[64]B. Halliwell and J. M. Gutteridge, "The antioxidants of human extracellular fluids," Arch Biochem Biophys, vol. 280, pp. 1-8, Jul 1990.
[65]陳素瑜, "骨骼型態發生蛋白質在大白鼠初級培養大腦皮質神經細胞的神經保護作用," in 生理學研究所碩士論文. vol. 碩士: 國防醫學院, 2001.[66]E. R. Whittemore, D. T. Loo, and C. W. Cotman, "Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons," Neuroreport, vol. 5, pp. 1485-8, Jul 21 1994.
[67]M. E. Rice, "Ascorbate regulation and its neuroprotective role in the brain," Trends Neurosci, vol. 23, pp. 209-16, May 2000.
[68]黃雅妮, "維生素c抑制膠質細胞被內毒素所誘發產生發炎媒介物質之機制是經由抑制有絲分裂因子-活化蛋白質激酶之活化," in 生理學研究所碩士論文. vol. 碩士: 國防醫學院, 2003.[69]H. Padh, "Cellular functions of ascorbic acid," Biochem Cell Biol, vol. 68, pp. 1166-73, Oct 1990.
[70]B. Halliwell, "Reactive oxygen species and the central nervous system," J Neurochem, vol. 59, pp. 1609-23, Nov 1992.
[71]V. L. Dawson and T. M. Dawson, "Nitric oxide neurotoxicity," J Chem Neuroanat, vol. 10, pp. 179-90, Jun 1996.
[72]M. Ebadi, S. K. Srinivasan, and M. D. Baxi, "Oxidative stress and antioxidant therapy in Parkinson''s disease," Prog Neurobiol, vol. 48, pp. 1-19, Jan 1996.
[73]C. Behl, "Alzheimer''s disease and oxidative stress: implications for novel therapeutic approaches," Prog Neurobiol, vol. 57, pp. 301-23, Feb 1999.
[74]W. R. Markesbery and J. M. Carney, "Oxidative alterations in Alzheimer''s disease," Brain Pathol, vol. 9, pp. 133-46, Jan 1999.
[75]E. D. Hall, P. K. Andrus, J. A. Oostveen, T. J. Fleck, and M. E. Gurney, "Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS," J Neurosci Res, vol. 53, pp. 66-77, Jul 1 1998.
[76]C. W. Olanow and G. W. Arendash, "Metals and free radicals in neurodegeneration," Curr Opin Neurol, vol. 7, pp. 548-58, Dec 1994.
[77]N. A. Simonian and J. T. Coyle, "Oxidative stress in neurodegenerative diseases," Annu Rev Pharmacol Toxicol, vol. 36, pp. 83-106, 1996.
[78]S. Fahn and G. Cohen, "The oxidant stress hypothesis in Parkinson''s disease: evidence supporting it," Ann Neurol, vol. 32, pp. 804-12, Dec 1992.
[79]P. Jenner, "Oxidative stress in Parkinson''s disease and other neurodegenerative disorders," Pathol Biol (Paris), vol. 44, pp. 57-64, Jan 1996.
[80]W. Retz, W. Gsell, G. Munch, M. Rosler, and P. Riederer, "Free radicals in Alzheimer''s disease," J Neural Transm Suppl, vol. 54, pp. 221-36, 1998.
[81]R. J. Ferrante, S. E. Browne, L. A. Shinobu, A. C. Bowling, M. J. Baik, U. MacGarvey, N. W. Kowall, R. H. Brown, Jr., and M. F. Beal, "Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis," J Neurochem, vol. 69, pp. 2064-74, Nov 1997.
[82]D. R. Brown, "Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence," Folia Neuropathol, vol. 43, pp. 229-43, 2005.
[83]A. Chavarria and J. Alcocer-Varela, "Is damage in central nervous system due to inflammation?," Autoimmun Rev, vol. 3, pp. 251-60, Jun 2004.
[84]鄭楚勳, "結合神經移植與添加aFGF在老鼠脊髓全斷模型中發炎反應之影響," in 生物技術研究所碩士論文. vol. 碩士: 朝陽科技大學, 2006.[85]M. A. Munoz-Fernandez and M. Fresno, "The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system," Prog Neurobiol, vol. 56, pp. 307-40, Oct 1998.
[86]D. Giulian, T. J. Baker, L. C. Shih, and L. B. Lachman, "Interleukin 1 of the central nervous system is produced by ameboid microglia," J Exp Med, vol. 164, pp. 594-604, Aug 1 1986.
[87]M. Sawada, N. Kondo, A. Suzumura, and T. Marunouchi, "Production of tumor necrosis factor-alpha by microglia and astrocytes in culture," Brain Res, vol. 491, pp. 394-7, Jul 10 1989.
[88]I. Y. Chung and E. N. Benveniste, "Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta," J Immunol, vol. 144, pp. 2999-3007, Apr 15 1990.
[89]M. C. Morganti-Kossmann, T. Kossmann, M. E. Brandes, S. E. Mergenhagen, and S. M. Wahl, "Autocrine and paracrine regulation of astrocyte function by transforming growth factor-beta," J Neuroimmunol, vol. 39, pp. 163-73, Jul 1992.
[90]B. Schobitz, D. A. Voorhuis, and E. R. De Kloet, "Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain," Neurosci Lett, vol. 136, pp. 189-92, Mar 2 1992.
[91]R. L. Gendron, F. P. Nestel, W. S. Lapp, and M. G. Baines, "Expression of tumor necrosis factor alpha in the developing nervous system," Int J Neurosci, vol. 60, pp. 129-36, Sep 1991.
[92]C. D. Breder, M. Tsujimoto, Y. Terano, D. W. Scott, and C. B. Saper, "Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system," J Comp Neurol, vol. 337, pp. 543-67, Nov 22 1993.
[93]E. Obregon, M. C. Punzon, J. Gonzalez-Nicolas, E. Fernandez-Cruz, M. Fresno, and M. A. Munoz-Fernandez, "Induction of adhesion/differentiation of human neuroblastoma cells by tumour necrosis factor-alpha requires the expression of an inducible nitric oxide synthase," Eur J Neurosci, vol. 9, pp. 1184-93, Jun 1997.
[94]F. R. Jirik, T. J. Podor, T. Hirano, T. Kishimoto, D. J. Loskutoff, D. A. Carson, and M. Lotz, "Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells," J Immunol, vol. 142, pp. 144-7, Jan 1 1989.
[95]Z. Fabry, K. M. Fitzsimmons, J. A. Herlein, T. O. Moninger, M. B. Dobbs, and M. N. Hart, "Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes," J Neuroimmunol, vol. 47, pp. 23-34, Aug 1993.
[96]J. Joseph, J. L. Grun, F. D. Lublin, and R. L. Knobler, "Interleukin-6 induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM)," J Neuroimmunol, vol. 42, pp. 47-52, Jan 1993.
[97]F. Bazzoni and B. Beutler, "The tumor necrosis factor ligand and receptor families," N Engl J Med, vol. 334, pp. 1717-25, Jun 27 1996.
[98]D. Wallach, "A decade of accumulated knowledge and emerging answers. The 6th international congress on TNF Rhodes, Greece. May 1996," Eur Cytokine Netw, vol. 7, pp. 713-24, Dec 1996.
[99]M. Kriegler, C. Perez, K. DeFay, I. Albert, and S. D. Lu, "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF," Cell, vol. 53, pp. 45-53, Apr 8 1988.
[100]L. Lafortune, J. Nalbantoglu, and J. P. Antel, "Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: comparison with adult microglia and fetal astrocytes," J Neuropathol Exp Neurol, vol. 55, pp. 515-21, May 1996.
[101]G. W. Kreutzberg, "Microglia: a sensor for pathological events in the CNS," Trends Neurosci, vol. 19, pp. 312-8, Aug 1996.
[102]C. A. Colton, O. N. Chernyshev, D. L. Gilbert, and M. P. Vitek, "Microglial contribution to oxidative stress in Alzheimer''s disease," Ann N Y Acad Sci, vol. 899, pp. 292-307, 2000.
[103]C. C. Chao, S. Hu, and P. K. Peterson, "Glia, cytokines, and neurotoxicity," Crit Rev Neurobiol, vol. 9, pp. 189-205, 1995.
[104]J. F. Kerr, A. H. Wyllie, and A. R. Currie, "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics," Br J Cancer, vol. 26, pp. 239-57, Aug 1972.
[105]A. Fraser and G. Evan, "A license to kill," Cell, vol. 85, pp. 781-4, Jun 14 1996.
[106]G. T. Williams and C. A. Smith, "Molecular regulation of apoptosis: genetic controls on cell death," Cell, vol. 74, pp. 777-9, Sep 10 1993.
[107]G. M. Cohen, "Caspases: the executioners of apoptosis," Biochem J, vol. 326 ( Pt 1), pp. 1-16, Aug 15 1997.
[108]G. Nunez, M. A. Benedict, Y. Hu, and N. Inohara, "Caspases: the proteases of the apoptotic pathway," Oncogene, vol. 17, pp. 3237-45, Dec 24 1998.
[109]D. K. Miller, "The role of the Caspase family of cysteine proteases in apoptosis," Semin Immunol, vol. 9, pp. 35-49, Feb 1997.
[110]T. M. Buttke and P. A. Sandstrom, "Oxidative stress as a mediator of apoptosis," Immunol Today, vol. 15, pp. 7-10, Jan 1994.
[111]J. F. Wang, T. R. Jerrells, and J. J. Spitzer, "Decreased production of reactive oxygen intermediates is an early event during in vitro apoptosis of rat thymocytes," Free Radic Biol Med, vol. 20, pp. 533-42, 1996.
[112]J. Y. Follezou, J. Emerit, and F. Bricaire, "[Neuro-degenerative diseases: role of reactive oxygen species and of apoptosis]," Presse Med, vol. 28, pp. 1661-6, Oct 9 1999.
[113]P. S. Sastry and K. S. Rao, "Apoptosis and the nervous system," J Neurochem, vol. 74, pp. 1-20, Jan 2000.
[114]K. Mielke and T. Herdegen, "JNK and p38 stresskinases--degenerative effectors of signal-transduction-cascades in the nervous system," Prog Neurobiol, vol. 61, pp. 45-60, May 2000.
[115]J. E. Albina, S. Cui, R. B. Mateo, and J. S. Reichner, "Nitric oxide-mediated apoptosis in murine peritoneal macrophages," J Immunol, vol. 150, pp. 5080-5, Jun 1 1993.
[116]R. R. Ratan, T. H. Murphy, and J. M. Baraban, "Oxidative stress induces apoptosis in embryonic cortical neurons," J Neurochem, vol. 62, pp. 376-9, Jan 1994.
[117]L. A. Greene and A. S. Tischler, "Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor," Proc Natl Acad Sci U S A, vol. 73, pp. 2424-8, Jul 1976.
[118]林怡, "由細胞黏著力探討川芎嗪對氧糖剝奪損傷的Pc12細胞之保護作用," in 醫學工程研究所碩士論文. vol. 碩士: 國立成功大學, 2007.[119]H. Kamata, C. Tanaka, H. Yagisawa, S. Matsuda, Y. Gotoh, E. Nishida, and H. Hirata, "Suppression of nerve growth factor-induced neuronal differentiation of PC12 cells. N-acetylcysteine uncouples the signal transduction from ras to the mitogen-activated protein kinase cascade," J Biol Chem, vol. 271, pp. 33018-25, Dec 20 1996.
[120]S. Katoh, Y. Mitsui, K. Kitani, and T. Suzuki, "Hyperoxia induces the differentiated neuronal phenotype of PC12 cells by producing reactive oxygen species," Biochem Biophys Res Commun, vol. 241, pp. 347-51, Dec 18 1997.
[121]S. Leppa, R. Saffrich, W. Ansorge, and D. Bohmann, "Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation," Embo J, vol. 17, pp. 4404-13, Aug 3 1998.
[122]T. Morooka and E. Nishida, "Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells," J Biol Chem, vol. 273, pp. 24285-8, Sep 18 1998.
[123]M. Obin, E. Mesco, X. Gong, A. L. Haas, J. Joseph, and A. Taylor, "Neurite outgrowth in PC12 cells. Distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis," J Biol Chem, vol. 274, pp. 11789-95, Apr 23 1999.
[124]C. Eliasson, C. Sahlgren, C. H. Berthold, J. Stakeberg, J. E. Celis, C. Betsholtz, J. E. Eriksson, and M. Pekny, "Intermediate filament protein partnership in astrocytes," J Biol Chem, vol. 274, pp. 23996-4006, Aug 20 1999.
[125]N. J. Abbott, L. Ronnback, and E. Hansson, "Astrocyte-endothelial interactions at the blood-brain barrier," Nat Rev Neurosci, vol. 7, pp. 41-53, Jan 2006.
[126]R. C. Koehler, D. Gebremedhin, and D. R. Harder, "Role of astrocytes in cerebrovascular regulation," J Appl Physiol, vol. 100, pp. 307-17, Jan 2006.
[127]G. Seifert, K. Schilling, and C. Steinhauser, "Astrocyte dysfunction in neurological disorders: a molecular perspective," Nat Rev Neurosci, vol. 7, pp. 194-206, Mar 2006.
[128]鄒博成, "探討重金屬鎘誘發星狀膠細胞氧化傷害及鞣花酸抑制鎘導致的氧化傷害之機轉," in 生命科學系碩士論文. vol. 碩士: 國立成功大學, 2006.[129]T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," J Immunol Methods, vol. 65, pp. 55-63, Dec 16 1983.
[130]Y. Liu, "Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostatis," Prog Neuropsychopharmacol Biol Psychiatry, vol. 23, pp. 377-95, Apr 1999.
[131]詹惠雯, "探討脈衝式電磁場促進類骨母細胞增生之機轉," in 醫學工程研究所碩士. vol. 碩士: 中原大學, 2003.[132]J. Y. Koh and D. W. Choi, "Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay," J Neurosci Methods, vol. 20, pp. 83-90, May 1987.
[133]王志煜, "氧化壓力誘導培養之大白鼠大腦皮質細胞凋亡：神經細胞與神經膠質細胞之不同反應性," in 生命科學研究所博士論文. vol. 博士: 國防醫學院, 2003.[134]D. C. Ferris, J. Kume-Kick, I. Russo-Menna, and M. E. Rice, "Gender differences in cerebral ascorbate levels and ascorbate loss in ischemia," Neuroreport, vol. 6, pp. 1485-9, Jul 31 1995.
[135]K. H. Masaki, K. G. Losonczy, G. Izmirlian, D. J. Foley, G. W. Ross, H. Petrovitch, R. Havlik, and L. R. White, "Association of vitamin E and C supplement use with cognitive function and dementia in elderly men," Neurology, vol. 54, pp. 1265-72, Mar 28 2000.
[136]W. J. Perrig, P. Perrig, and H. B. Stahelin, "The relation between antioxidants and memory performance in the old and very old," J Am Geriatr Soc, vol. 45, pp. 718-24, Jun 1997.
[137]S. Yallampalli, M. A. Micci, and G. Taglialatela, "Ascorbic acid prevents beta-amyloid-induced intracellular calcium increase and cell death in PC12 cells," Neurosci Lett, vol. 251, pp. 105-8, Jul 24 1998.
[138]H. J. Heo and C. Y. Lee, "Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration," J Agric Food Chem, vol. 52, pp. 7514-7, Dec 15 2004.
[139]J. H. Song, S. H. Shin, and G. M. Ross, "Prooxidant effects of ascorbate in rat brain slices," J Neurosci Res, vol. 58, pp. 328-36, Oct 15 1999.
[140]J. H. Song, S. H. Shin, W. Wang, and G. M. Ross, "Involvement of oxidative stress in ascorbate-induced proapoptotic death of PC12 cells," Exp Neurol, vol. 169, pp. 425-37, Jun 2001.
[141]J. Feng, A. H. Melcher, D. M. Brunette, and H. K. Moe, "Determination of L-ascorbic acid levels in culture medium: concentrations in commercial media and maintenance of levels under conditions of organ culture," In Vitro, vol. 13, pp. 91-9, Feb 1977.
[142]H. Sakagami, K. Satoh, H. Ohata, H. Takahashi, H. Yoshida, M. Iida, N. Kuribayashi, T. Sakagami, K. Momose, and M. Takeda, "Relationship between ascorbyl radical intensity and apoptosis-inducing activity," Anticancer Res, vol. 16, pp. 2635-44, Sep-Oct 1996.
[143]R. W. Welch, Y. Wang, A. Crossman, Jr., J. B. Park, K. L. Kirk, and M. Levine, "Accumulation of vitamin C (ascorbate) and its oxidized metabolite dehydroascorbic acid occurs by separate mechanisms," J Biol Chem, vol. 270, pp. 12584-92, May 26 1995.
[144]J. C. Vera, C. I. Rivas, F. V. Velasquez, R. H. Zhang, Concha, II, and D. W. Golde, "Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid," J Biol Chem, vol. 270, pp. 23706-12, Oct 6 1995.
[145]F. C. Ngkeekwong and L. L. Ng, "Two distinct uptake mechanisms for ascorbate and dehydroascorbate in human lymphoblasts and their interaction with glucose," Biochem J, vol. 324 ( Pt 1), pp. 225-30, May 15 1997.
[146]A. M. Bode, C. R. Yavarow, D. A. Fry, and T. Vargas, "Enzymatic basis for altered ascorbic acid and dehydroascorbic acid levels in diabetes," Biochem Biophys Res Commun, vol. 191, pp. 1347-53, Mar 31 1993.
[147]A. Paolicchi, A. Pezzini, M. Saviozzi, S. Piaggi, M. Andreuccetti, E. Chieli, G. Malvaldi, and A. F. Casini, "Localization of a GSH-dependent dehydroascorbate reductase in rat tissues and subcellular fractions," Arch Biochem Biophys, vol. 333, pp. 489-95, Sep 15 1996.
[148]M. Coassin, A. Tomasi, V. Vannini, and F. Ursini, "Enzymatic recycling of oxidized ascorbate in pig heart: one-electron vs two-electron pathway," Arch Biochem Biophys, vol. 290, pp. 458-62, Nov 1 1991.
[149]E. N. Benveniste and D. J. Benos, "TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function," Faseb J, vol. 9, pp. 1577-84, Dec 1995.
[150]A. P. Lieberman, P. M. Pitha, H. S. Shin, and M. L. Shin, "Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus," Proc Natl Acad Sci U S A, vol. 86, pp. 6348-52, Aug 1989.
[151]M. C. Morganti-Kossman, P. M. Lenzlinger, V. Hans, P. Stahel, E. Csuka, E. Ammann, R. Stocker, O. Trentz, and T. Kossmann, "Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue," Mol Psychiatry, vol. 2, pp. 133-6, Mar 1997.
[152]M. Pickering, D. Cumiskey, and J. J. O''Connor, "Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system," Exp Physiol, vol. 90, pp. 663-70, Sep 2005.
[153]J. H. Hsu, S. S. Liou, B. C. Yu, J. T. Cheng, and Y. C. Wu, "Activation of alpha1A-adrenoceptor by andrographolide to increase glucose uptake in cultured myoblast C2C12 cells," Planta Med, vol. 70, pp. 1230-3, Dec 2004.
[154]B. C. Yu, C. K. Chang, C. F. Su, and J. T. Cheng, "Mediation of beta-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals," Naunyn Schmiedebergs Arch Pharmacol, vol. 377, pp. 529-40, Jun 2008.
[155]I. Ginis, J. M. Hallenbeck, J. Liu, M. Spatz, R. Jaiswal, and E. Shohami, "Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappaB," Mol Med, vol. 6, pp. 1028-41, Dec 2000.
[156]V. Trembovler, S. Abu-Raya, and E. Shohami, "Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells," Neurosci Lett, vol. 353, pp. 115-8, Dec 19 2003.
[157]D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, and M. R. Boyd, "Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines," Cancer Res, vol. 48, pp. 4827-33, Sep 1 1988.
[158]M. V. Berridge and A. S. Tan, "Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction," Arch Biochem Biophys, vol. 303, pp. 474-82, Jun 1993.
[159]Y. Liu, D. A. Peterson, H. Kimura, and D. Schubert, "Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction," J Neurochem, vol. 69, pp. 581-93, Aug 1997.
[160]F. P. Altman, "Tetrazolium salts and formazans," Prog Histochem Cytochem, vol. 9, pp. 1-56, 1976.
[161]M. S. Shearman, S. R. Hawtin, and V. J. Tailor, "The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides," J Neurochem, vol. 65, pp. 218-27, Jul 1995.